-
Mashup Score: 0Optimizing initial therapy of CLL - 7 month(s) ago
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the specific considerations for optimizing chronic lymphocytic leukemia (CLL) treatment in patients in the frontline setting. These include age, comorbidities, length of treatment (time-limited or continuous), and access to lines of therapy. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Non-Malignant Blood Disorders | VJHemOnc - 7 month(s) ago
Explore the latest updates and expert interviews in non-malignant blood disorders on The Non-Malignant Channel by VJHemOnc
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
You may have noticed our logo has changed... ๐๐ฉธ We now have a Non-Malignant Channel! We are committed to providing you with comprehensive insights into #blooddisorders, from #cancers to #nonmalignant conditions ๐ฌ ๐ https://t.co/DCGCNNnXP8 Our regular #HemOnc content willโฆ https://t.co/zZS7eLlMsS https://t.co/HvYGWi1s0S
-
-
Mashup Score: 0MDS Sessions: Updates on the diagnosis, risk stratification and treatment of lower-risk MDS | VJHemOnc - 7 month(s) ago
Skip to content Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional. Visit …
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Arun Wiita, PhD, University of California, San Francisco, CA, shares some insights into the use of mass spectrometry-based proteomics in multiple myeloma, highlighting the value of this novel approach in improving research in the field. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Clinical guidance for the use of bispecific antibodies in NHL - 7 month(s) ago
In this video, Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the unique toxicity profile associated with bispecific antibodies and provides guidance for physicians treating patients with non-Hodgkin lymphoma (NHL) using this class of agents. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Socioeconomic and racial disparities in myeloma trial recruitment - 7 month(s) ago
Amrutha Sridhar, MBBS, University College London Hospitals, London, UK, discusses how socioeconomic and racial inequalities persist during the enrollment process in multiple myeloma clinical trials. Patients from a lower socioeconomic background are underrepresented in clinical trials, and will have worse overall survival, even after receiving treatment. Gaps in outcomes are additionally more pronounced in older patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0iwCLL 2023 | VJHemOnc - 7 month(s) ago
The biennial International Workshop on Chronic Lymphocytic Leukemia TM (XX iwCLL 2023) will be held in Boston, MA, from October 6-9, 2023, and will be an opportunity for international hemonc leaders from all over the world to discuss the latest updates in the pathobiology and treatment of CLL. The biennial International Workshop on Chronic Lymphocytic Leukemia TM (XX iwCLL 2023) will be hel d in Boston, MA, from October 6-9, 2023, and will be an opportunity for international hemonc leaders from all over
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Transplant Sessions: Should patients with AML receive treatment before transplantation? | VJHemOnc - 7 month(s) ago
Welcome to the Transplant Sessions brought to you by the Video Journal of Hematological Oncology (VJHemOnc). In this session, leading experts Johannes Schetelig, MD, DKMS Group and TU Dresden, Dresden, Germany, and Gesine Bug, MD, Goethe University Frankfurt, Frankfurt, Germany, discuss whether patients with acute myeloid leukemia (AML) should receive treatment before stem cell transplantation (SCT), which was presented and debated at the 2023 SOHO Annual Meeting. The experts further discuss findings
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Classifying frailty and approaching elderly patients with lymphoma - 7 month(s) ago
While the treatment landscape of both Hodgkin and non-Hodgkin lymphoma (HL; NHL) has improved in recent years, there are several…
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0e-Learning Activities for Hematological Oncology - VJAcademy - 7 month(s) ago
Explore our selection of e-learning activities designed to support the continuing education of healthcare professionals working in hematological oncology.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEW #CME accredited VJAcademy course on #AML ๐ป ๐ฉธ๐ฌ With leading #HemOnc experts Charles Craddock, @EuniceWangMD & @Daver_Leukemia VJAcademy is our FREE-access e-learning platform which aims to support the continuing education of #HCPs in #HemOnc๐ก ๐ https://t.co/18Oo9a3XEM https://t.co/3eGiZ1UuHE
-
๐ฅ @DrMDavids of @DanaFarber shares insights into optimizing CLL therapy for patients in the front-line setting - a hot topic at this yearโs #iwCLL2023 meeting! Check it out here: ๐https://t.co/CAsNBSmvUL #CLLsm #HemOnc @iwCLL #LeuSM